Related Experiment Video
Updated: Jan 16, 2026
Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
Published on: June 9, 2018
Serum Transthyretin as Prognostic Biomarker for Cardiovascular Events and Mortality: A Systematic Review and
Dimitrios Terentes-Printzios1, Maria Eleni Koilakou1, Polyxeni Alexiou1
1First Cardiology Department, Hippokration General Hospital, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Background:
Serum transthyretin (TTR) levels, a key player in the occurrence of amyloidosis, have also emerged as a potential biomarker in cardiovascular (CV) disease and all-cause mortality. However, it is unclear whether TTR levels predict future events.
Objectives:
This meta-analysis sought to evaluate the prognostic utility in longitudinal studies of serum TTR levels in predicting CV events, heart failure (HF), CV mortality, and all-cause mortality across diverse patient populations.
Methods:
A systematic literature search was conducted across major electronic databases and gray literature up to May 2025. Studies reporting HRs or risk estimates for the association between serum TTR levels and outcomes of interest (CV events and mortality) were included. Two reviewers extracted data independently and summary estimates of association were obtained using a random-effects model. The primary outcomes were risk ratios for total CV events, HF, all-cause mortality, and CV mortality.
Results:
A total of 34 studies involving 83,929 participants, 50.5% females, mean age 61.45 years old, and a mean follow-up of 41 months were included in the analysis. Low serum TTR levels were found to be significantly associated with an increased risk of CV events (HR: 1.54; 95% CI: 1.30-1.83; P < 0.001), all-cause mortality (HR: 1.65; 95% CI: 1.50-1.82; P < 0.001), CV mortality (HR: 2.08; 95% CI: 1.26-3.44; P = 0.004), and heart failure (HR: 1.72; 95% CI: 1.35-2.21; P < 0.001). A decrease in TTR by 10 mg/dL corresponded with an increase in risk of 30%, 73%, 46%, and 28% in total CV, all-cause mortality, CV mortality, and HF, respectively. In meta-regression analysis, low TTR levels in younger male subjects, preserved ejection fraction and elevated N-terminal pro-B-type natriuretic peptide levels were associated with a higher risk of all-cause mortality.
Conclusions:
Serum TTR is a predictor of CV events, all-cause and CV mortality, and HF across different populations, underscoring its potential use as a CV biomarker and instigating research on the possible clinical role of TTR medications in other clinical settings other than amyloidosis.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests